Trombo ACC tabs 100mcg #100

Instruction for Trombo ACC

You can buy Trombo ACC on this page

Trombo ACC is a drug with antiaggregatory action.

Release form and composition

Dosage form release Trombo ACC - enteric film coated tablets: white, biconvex, round, shiny, with a smooth or somewhat rough surface (14 pcs. In blisters, in a cardboard box 2 blisters; 20 pcs. In blisters, in a cardboard box pack of 5 blisters).
1 tablet contains:
    active substance: acetylsalicylic acid - 50 or 100 mg;
    auxiliary components (50/100 mg): colloidal silicon dioxide - 1.5 / 3 mg; lactose monohydrate - 65/60 mg; potato starch - 5/10 mg; microcrystalline cellulose - 28.5 / 27 mg;
    shell (50/100 mg): talc - 2.53 / 3.795 mg; triacetin - 0.68 / 1.02 mg; copolymer of ethyl acrylate and methacrylic acid (1: 1) (Eudragit L) - 6.79 / 10.185 mg.
Indications for use
    unstable / stable angina pectoris;
    prevention of transient cerebral circulation;
    primary prevention of acute myocardial infarction in the presence of risk factors (for example, smoking, hyperlipidemia, diabetes mellitus, obesity, arterial hypertension, old age);
    secondary prevention of recurrent myocardial infarction;
    prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches, including the use in patients with prolonged immobilization due to major surgical interventions;
    stroke prevention, including use in patients with transient cerebrovascular accidents;
    prevention of thromboembolism after surgery and invasive interventions on vessels, including endarterectomy of the carotid arteries, coronary artery bypass grafting, stenting of coronary arteries, angioplasty.

Contraindications

Absolute:
    gastrointestinal bleeding;
    hemorrhagic diathesis;
    bronchial asthma associated with therapy with salicylates and other NSAIDs (non-steroidal anti-inflammatory drugs);
    exacerbation of erosive and ulcerative lesions of the gastrointestinal tract;
    severe hepatic impairment (on the Child - Pugh scale - class B and higher);
    severe renal failure (with creatinine clearance <30 ml / min);
    chronic heart failure (NYHA classification - III – IV functional class);
    a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and ASA (acetylsalicylic acid) intolerance;
    lactose intolerance, glucose-galactose malabsorption, lactase deficiency;
    combination therapy with methotrexate (from 15 mg per week);
    age under 18;
    I and III trimesters of pregnancy, breastfeeding period;
    individual intolerance to the components of the drug and other NSAIDs.
Relative (diseases / conditions in which the appointment of Trombo ACC requires caution):
    respiratory diseases in a chronic course;
    hyperuricemia;
    gout;
    peptic ulcer of the stomach and duodenum, gastrointestinal bleeding (anamnestic data);
    liver failure (below class B on the Child-Pugh scale);
    renal failure (with creatinine clearance from 30 ml / min);
    hay fever;
    bronchial asthma;
    drug allergy, including to analgesics, drugs of the NSAID group, drugs with antirheumatic and anti-inflammatory effects;
    polyposis of the nose;
    prospective surgical interventions, including minor ones;
    combined use with the following drugs: methotrexate (up to 15 mg per week), anticoagulants, digoxin, antiplatelet / thrombolytic agents, NSAIDs and salicylic acid derivatives (large doses), oral hypoglycemic agents (sulfonylurea derivatives), insulin, alcohol (including alcoholic beverages ), valproic acid, ibuprofen, selective serotonin reuptake inhibitors;
    II trimester of pregnancy (the use of Trombo ACC is possible only after assessing the ratio of benefit to risk, preferably with a short course at a dose of up to 150 mg per day).

Method of administration and dosage

Trombo ACC is taken orally with plenty of liquid, preferably before meals, but not on an empty stomach.
When used for the prevention of deep vein thrombosis and thromboembolism of the pulmonary artery Trombo ACC is prescribed at 100-200 mg per day. In other cases, the daily dose is 50-100 mg.
Long-term therapy is shown, its duration is determined by the doctor individually.

Side effects

The drug Trombo ACC is generally well tolerated by patients, which is associated with a low dosage.
In rare cases, the development of the following disorders is observed:
    digestive system: abdominal pain, nausea, vomiting, heartburn; rarely - stomach and duodenal ulcers, including perforation, gastrointestinal bleeding, transient hepatic dysfunction with increased activity of hepatic transaminases;
    hematopoietic system: an increase in the frequency of perioperative (intra- and postoperative) bleeding, nosebleeds, bleeding gums, hematomas, bleeding from the urinary tract; in some cases - serious cases of bleeding, including hemorrhages in the brain and gastrointestinal bleeding, which are life-threatening. Bleeding can lead to the appearance of post-hemorrhagic / iron deficiency anemia in acute or chronic course, proceeding with the corresponding symptoms (pallor, asthenia, hypoperfusion);
    nervous system: dizziness, tinnitus, hearing loss (may indicate an overdose);
    allergic reactions: cardio-respiratory distress syndrome, Quincke's edema, skin rash, urticaria, itching, rhinitis, bronchospasm, edema of the nasal mucosa, rhinitis, severe reactions including anaphylactic shock.

Special instructions

Trombo ACC should be used as directed by a doctor.
It should be taken into account that ASA can lead to the development of bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. The main risk factors are: a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, hypersensitivity reactions to other drugs (for example, itching, skin reactions, urticaria).
Since the duration of the inhibitory effect of ASA on platelet aggregation is several days, the likelihood of bleeding during surgery or in the postoperative period increases (in some cases, a complete rejection of Trombo ACC may be required for this time).
Low doses of ASA can lead to gout in predisposed patients (with reduced uric acid excretion).
Exceeding the dose of Trombo ACC increases the likelihood of gastrointestinal bleeding, which is especially dangerous for elderly patients.
Taking into account the profile of adverse reactions, including the likelihood of dizziness, while taking Trombo ACC, care must be taken when driving.

Drug interactions

The combined use of Trombo ACC with the following drugs leads to an increase in their action (a decrease in their dose may be required):
    anticoagulants, thrombolytic / antiplatelet drugs, including clopidogrel, ticlopidine: the likelihood of bleeding increases, which is associated with the synergism of the main therapeutic effects of these drugs;
    methotrexate: associated with a decrease in its renal clearance and its displacement from the connection with proteins;
    selective serotonin reuptake inhibitors: the likelihood of bleeding from the upper gastrointestinal tract increases, which is associated with synergism with ASA;
    drugs with an anticoagulant, antiplatelet or thrombolytic effect: the damaging effect on the mucous membrane of the gastrointestinal tract is enhanced;
    oral hypoglycemic agents (sulfonylurea derivatives), insulin: associated with the hypoglycemic properties of ASA;
    digoxin: associated with a decrease in its renal excretion, which can lead to an overdose;
    NSAIDs and salicylic acid derivatives in high doses: the likelihood of an ulcerogenic effect and bleeding from the gastrointestinal tract increases, which is associated with a synergistic action;
    valproic acid: its toxicity increases, which is associated with its displacement from the connection with blood plasma proteins;
    ethanol: the likelihood of damage to the mucous membrane of the gastrointestinal tract and lengthening of bleeding time increases, which is associated with a mutual enhancement of effects;
    ibuprofen: the cardioprotective effect of ASA decreases, which is associated with antagonism in relation to irreversible inhibition of platelets.
The combined use of Trombo ACC with the following drugs leads to a weakening of their action (their dose may need to be adjusted):
    any diuretics: glomerular filtration rate decreases;
    drugs with uricosuric action, including probenecid, benzbromarone: the uricosuric effect decreases;
    angiotensin-converting enzyme inhibitors: the glomerular filtration rate decreases (dose-dependently);
    systemic glucocorticosteroids (except for hydrocortisone, which is used in Addison's disease for replacement therapy): the excretion of salicylates increases and, accordingly, their effect is weakened.

Terms and conditions of storage

Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.
Shelf life is 3 years.

Terms of sell

You don't need a prescription from a doctor to buy Trombo ACC.